17 results on '"Hamelmann, Eckard"'
Number of results to display per page
Search Results
2. Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children
- Author
-
Hamelmann, Eckard, primary, Hammerby, Eva, additional, Scharling, Katrine Skaarup, additional, Pedersen, Mikkel, additional, Okkels, Anna, additional, and Schmitt, Jochen, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children.
- Author
-
Hamelmann, Eckard, Hammerby, Eva, Scharling, Katrine Skaarup, Pedersen, Mikkel, Okkels, Anna, and Schmitt, Jochen
- Subjects
- *
SUBLINGUAL immunotherapy , *ALLERGIC rhinitis , *MARKOV processes , *MEDICAL care costs , *ALLERGY desensitization , *SEASONAL variations of diseases - Abstract
Background: Allergic rhinitis (AR) is a chronic inflammatory disease of the upper airway, which progresses into allergic asthma (AA) in up to 45% of children. This analysis aimed to investigate clinical and economic benefits of sublingual allergen immunotherapy (SLIT tablets) initiated early in childhood for the treatment of AR by quantifying the long‐term reduction in new cases of AA. Methods: A Markov model was developed to estimate the long‐term effects of SLIT tablets on the risk of developing asthma. Key parameters were primarily based on data from the GRAZAX® Asthma Prevention trial and included the age‐ and treatment‐dependent risk of developing AA as well as annual probabilities of progression/remission in AR severity. Healthcare costs were estimated using data from the REACT study. Results: In a modelled cohort of children with moderate‐to‐severe seasonal AR initiated on SLIT tablets at ages 7 and 12, 24% and 29%, respectively, develop AA during a 20‐year period. In comparison, when initiated at age 5, 19% develop AA. Additionally, initiation of SLIT tablets at age 5 is associated with a total healthcare cost of EUR 20,429 per patient, whereas initiation at ages 7 and 12 is associated with, respectively, EUR 21,050 and EUR 22,379 per patient 20 years after AR diagnosis. Conclusion: Initiation of SLIT tablets in early childhood is associated with a clinically meaningful and permanent reduction in new cases of AA and lower healthcare costs among children with AR. This finding supports the clinical relevance of initiating SLIT tablets early for children with AR to obtain long‐term clinical benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper
- Author
-
Kappen, Jasper, primary, Diamant, Zuzana, additional, Agache, Ioana, additional, Bonini, Matteo, additional, Bousquet, Jean, additional, Canonica, G. Walter, additional, Durham, Stephen R., additional, Guibas, George V., additional, Hamelmann, Eckard, additional, Jutel, Marek, additional, Papadopoulos, Nikolaos G., additional, Roberts, Graham, additional, Shamji, Mohamed H., additional, Zieglmayer, Petra, additional, Gerth van Wijk, Roy, additional, and Pfaar, Oliver, additional
- Published
- 2023
- Full Text
- View/download PDF
5. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
- Author
-
Zuberbier, Torsten, primary, Abdul Latiff, Amir Hamzah, additional, Abuzakouk, Mohamed, additional, Aquilina, Susan, additional, Asero, Riccardo, additional, Baker, Diane, additional, Ballmer‐Weber, Barbara, additional, Bangert, Christine, additional, Ben‐Shoshan, Moshe, additional, Bernstein, Jonathan A., additional, Bindslev‐Jensen, Carsten, additional, Brockow, Knut, additional, Brzoza, Zenon, additional, Chong Neto, Herberto Jose, additional, Church, Martin K., additional, Criado, Paulo R., additional, Danilycheva, Inna V., additional, Dressler, Corinna, additional, Ensina, Luis Felipe, additional, Fonacier, Luz, additional, Gaskins, Matthew, additional, Gáspár, Krisztian, additional, Gelincik, Aslı, additional, Giménez‐Arnau, Ana, additional, Godse, Kiran, additional, Gonçalo, Margarida, additional, Grattan, Clive, additional, Grosber, Martine, additional, Hamelmann, Eckard, additional, Hébert, Jacques, additional, Hide, Michihiro, additional, Kaplan, Allen, additional, Kapp, Alexander, additional, Kessel, Aharon, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Larenas‐Linnemann, Désirée, additional, Lauerma, Antti, additional, Leslie, Tabi A., additional, Magerl, Markus, additional, Makris, Michael, additional, Meshkova, Raisa Y., additional, Metz, Martin, additional, Micallef, Daniel, additional, Mortz, Charlotte G., additional, Nast, Alexander, additional, Oude‐Elberink, Hanneke, additional, Pawankar, Ruby, additional, Pigatto, Paolo D., additional, Ratti Sisa, Hector, additional, Rojo Gutiérrez, María Isabel, additional, Saini, Sarbjit S., additional, Schmid‐Grendelmeier, Peter, additional, Sekerel, Bulent E., additional, Siebenhaar, Frank, additional, Siiskonen, Hanna, additional, Soria, Angele, additional, Staubach‐Renz, Petra, additional, Stingeni, Luca, additional, Sussman, Gordon, additional, Szegedi, Andrea, additional, Thomsen, Simon Francis, additional, Vadasz, Zahava, additional, Vestergaard, Christian, additional, Wedi, Bettina, additional, Zhao, Zuotao, additional, and Maurer, Marcus, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus
- Author
-
Hagemann, Jan, primary, Onorato, Gabrielle L., additional, Jutel, Marek, additional, Akdis, Cezmi A., additional, Agache, Ioana, additional, Zuberbier, Torsten, additional, Czarlewski, Wienczyslawa, additional, Mullol, Joaquim, additional, Bedbrook, Anna, additional, Bachert, Claus, additional, Bennoor, Kazi S., additional, Bergmann, Karl‐Christian, additional, Braido, Fulvio, additional, Camargos, Paulo, additional, Caraballo, Luis, additional, Cardona, Victoria, additional, Casale, Thomas, additional, Cecchi, Lorenzo, additional, Chivato, Tomas, additional, Chu, Derek K., additional, Cingi, Cemal, additional, Correia‐de‐Sousa, Jaime, additional, del Giacco, Stefano, additional, Dokic, Dejan, additional, Dykewicz, Mark, additional, Ebisawa, Motohiro, additional, El‐Gamal, Yehia, additional, Emuzyte, Regina, additional, Fauquert, Jean‐Luc, additional, Fiocchi, Alessandro, additional, Fokkens, Wytske J., additional, Fonseca, Joao A., additional, Gemicioglu, Bilun, additional, Gomez, René‐Maximiliano, additional, Gotua, Maia, additional, Haahtela, Tari, additional, Hamelmann, Eckard, additional, Iinuma, Tomohisa, additional, Ivancevich, Juan Carlos, additional, Jassem, Ewa, additional, Kalayci, Omer, additional, Kardas, Przemyslaw, additional, Khaitov, Musa, additional, Kuna, Piotr, additional, Kvedariene, Violeta, additional, Larenas‐Linnemann, Desiree E., additional, Lipworth, Brian, additional, Makris, Michael, additional, Maspero, Jorge F., additional, Miculinic, Neven, additional, Mihaltan, Florin, additional, Mohammad, Yousser, additional, Montefort, Stephen, additional, Morais‐Almeida, Mario, additional, Mösges, Ralph, additional, Naclerio, Robert, additional, Neffen, Hugo, additional, Niedoszytko, Marek, additional, O’Hehir, Robyn E., additional, Ohta, Ken, additional, Okamoto, Yoshitaka, additional, Okubo, Kimi, additional, Panzner, Petr, additional, Papadopoulos, Nikolaos G., additional, Passalacqua, Giovanni, additional, Patella, Vincenzo, additional, Pereira, Ana, additional, Pfaar, Oliver, additional, Plavec, Davor, additional, Popov, Todor A., additional, Prokopakis, Emmanuel P., additional, Puggioni, Francesca, additional, Raciborski, Filip, additional, Reijula, Jere, additional, Regateiro, Frederico S., additional, Reitsma, Sietze, additional, Romano, Antonino, additional, Rosario, Nelson, additional, Rottem, Menachem, additional, Ryan, Dermot, additional, Samolinski, Boleslaw, additional, Sastre, Joaquin, additional, Solé, Dirceu, additional, Sova, Milan, additional, Stellato, Cristiana, additional, Suppli‐Ulrik, Charlotte, additional, Tsiligianni, Ioanna, additional, Valero, Antonio, additional, Valiulis, Arunas, additional, Valovirta, Erkka, additional, Vasankari, Tuula, additional, Ventura, Maria Teresa, additional, Wallace, Dana, additional, Wang, De Yun, additional, Williams, Siân, additional, Yorgancioglu, Arzu, additional, Yusuf, Osman M., additional, Zernotti, Mario, additional, Bousquet, Jean, additional, and Klimek, Ludger, additional
- Published
- 2021
- Full Text
- View/download PDF
7. ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
- Author
-
Bousquet, Jean, primary, Jutel, Marek, additional, Akdis, Cezmi A., additional, Klimek, Ludger, additional, Pfaar, Oliver, additional, Nadeau, Kari C., additional, Eiwegger, Thomas, additional, Bedbrook, Anna, additional, Ansotegui, Ignacio J., additional, Anto, Josep M., additional, Bachert, Claus, additional, Bateman, Eric D., additional, Bennoor, Kazi S., additional, Berghea, Elena Camelia, additional, Bergmann, Karl‐Christian, additional, Blain, Hubert, additional, Bonini, Mateo, additional, Bosnic‐Anticevich, Sinthia, additional, Boulet, Louis‐Philippe, additional, Brussino, Luisa, additional, Buhl, Roland, additional, Camargos, Paulo, additional, Canonica, Giorgio Walter, additional, Cardona, Victoria, additional, Casale, Thomas, additional, Chinthrajah, Sharon, additional, Akdis, Mübeccel, additional, Chivato, Tomas, additional, Christoff, George, additional, Cruz, Alvaro A., additional, Czarlewski, Wienczyslawa, additional, Del Giacco, Stefano, additional, Du, Hui, additional, El‐Gamal, Yehia, additional, Fokkens, Wytske J., additional, Fonseca, Joao A., additional, Gao, Yadong, additional, Gaga, Mina, additional, Gemicioglu, Bilun, additional, Gotua, Maia, additional, Haahtela, Tari, additional, Halpin, David, additional, Hamelmann, Eckard, additional, Hoffmann‐Sommergruber, Karin, additional, Humbert, Marc, additional, Ilina, Nataliya, additional, Ivancevich, Juan‐Carlos, additional, Joos, Guy, additional, Khaitov, Musa, additional, Kirenga, Bruce, additional, Knol, Edward F., additional, Ko, Fanny W., additional, Koskinen, Seppo, additional, Kowalski, Marek L., additional, Kraxner, Helga, additional, Kudlay, Dmitry, additional, Kuna, Piotr, additional, Kupczyk, Maciej, additional, Kvedariene, Violeta, additional, Abdul Latiff, Amir H., additional, Le, Lan T., additional, Levin, Michael, additional, Larenas‐Linnemann, Desiree, additional, Louis, Renaud, additional, Masjedi, Mohammad R., additional, Melén, Erik, additional, Mihaltan, Florin, additional, Milenkovic, Branislava, additional, Mohammad, Yousser, additional, Morais‐Almeida, Mario, additional, Mullol, Joaquim, additional, Namazova, Leyla, additional, Neffen, Hugo, additional, Nunes, Elisabete, additional, O’Byrne, Paul, additional, O’Hehir, Robyn, additional, O’Mahony, Liam, additional, Ohta, Ken, additional, Okamoto, Yoshitaka, additional, Onorato, Gabrielle L., additional, Panzner, Petr, additional, Papadopoulos, Nikos G., additional, Passalacqua, Gianni, additional, Patella, Vincenzo, additional, Pawankar, Ruby, additional, Pham‐Thi, Nhân, additional, Pigearias, Bernard, additional, Popov, Todor A., additional, Puggioni, Francesca, additional, Regateiro, Frederico S., additional, Rolla, Giovanni, additional, Rottem, Menachem, additional, Samolinski, Boleslaw, additional, Sastre, Joaquin, additional, Schwarze, Jurgen, additional, Sheikh, Aziz, additional, Scichilone, Nicola, additional, Soto‐Quiros, Manuel, additional, Soto‐Martinez, Manuel, additional, Sova, Milan, additional, Nicola, Stefania, additional, Stelmach, Rafael, additional, Suppli‐Ulrik, Charlotte, additional, Taborda‐Barata, Luis, additional, To, Teresa, additional, Tomazic, Peter‐Valentin, additional, Toppila‐Salmi, Sanna, additional, Tsiligianni, Ioanna, additional, Usmani, Omar, additional, Valiulis, Arunas, additional, Ventura, Maria Teresa, additional, Viegi, Giovanni, additional, Vontetsianos, Theodor, additional, Wang, De Yun, additional, Williams, Sian, additional, Wong, Gary W. K., additional, Yorgancioglu, Arzu, additional, Zernotti, Mario, additional, Zidarn, Mihaela, additional, Zuberbier, Torsten, additional, and Agache, Ioana, additional
- Published
- 2020
- Full Text
- View/download PDF
8. EAACI Biologicals Guidelines—Recommendations for severe asthma
- Author
-
Agache, Ioana, primary, Akdis, Cezmi A., additional, Akdis, Mubeccel, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Chu, Derek K., additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Flood, Breda, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Hernández‐Martín, Irene, additional, Knibb, Rebeca, additional, Mäkelä, Mika, additional, Nair, Parameswaran, additional, O’Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Pfaar, Oliver, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Palomares, Oscar, additional, and Jutel, Marek, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
- Author
-
Agache, Ioana, primary, Rocha, Claudio, additional, Beltran, Jessica, additional, Song, Yang, additional, Posso, Margarita, additional, Solà, Ivan, additional, Alonso‐Coello, Pablo, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canonica, Giorgio W., additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Martín, Irene Hernández, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Canelo‐Aybar, Carlos, additional, Palomares, Oscar, additional, and Jutel, Marek, additional
- Published
- 2020
- Full Text
- View/download PDF
10. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma
- Author
-
Agache, Ioana, primary, Song, Yang, additional, Rocha, Claudio, additional, Beltran, Jessica, additional, Posso, Margarita, additional, Steiner, Corinna, additional, Alonso‐Coello, Pablo, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Martín, Irene Hernández, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Schwarze, Jurgen, additional, Canelo‐Aybar, Carlos, additional, Palomares, Oscar, additional, and Jutel, Marek, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
- Author
-
Agache, Ioana, primary, Beltran, Jessica, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Canelo‐Aybar, Carlos, additional, Canonica, Giorgio Walter, additional, Casale, Thomas, additional, Chivato, Tomas, additional, Corren, Jonathan, additional, Del Giacco, Stefano, additional, Eiwegger, Thomas, additional, Firinu, Davide, additional, Gern, James E., additional, Hamelmann, Eckard, additional, Hanania, Nicola, additional, Mäkelä, Mika, additional, Hernández‐Martín, Irene, additional, Nair, Parameswaran, additional, O'Mahony, Liam, additional, Papadopoulos, Nikolaos G., additional, Papi, Alberto, additional, Park, Hae‐Sim, additional, Pérez de Llano, Luis, additional, Posso, Margarita, additional, Rocha, Claudio, additional, Quirce, Santiago, additional, Sastre, Joaquin, additional, Shamji, Mohamed, additional, Song, Yang, additional, Steiner, Corinna, additional, Schwarze, Jurgen, additional, Alonso‐Coello, Pablo, additional, Palomares, Oscar, additional, and Jutel, Marek, additional
- Published
- 2020
- Full Text
- View/download PDF
12. Toward clinically applicable biomarkers for asthma: An EAACI position paper
- Author
-
Diamant, Zuzana, primary, Vijverberg, Susanne, additional, Alving, Kjell, additional, Bakirtas, Arzu, additional, Bjermer, Leif, additional, Custovic, Adnan, additional, Dahlen, Sven‐Erik, additional, Gaga, Mina, additional, Gerth van Wijk, Roy, additional, Del Giacco, Stefano, additional, Hamelmann, Eckard, additional, Heaney, Liam G., additional, Heffler, Enrico, additional, Kalayci, Ömer, additional, Kostikas, Konstantinos, additional, Lutter, Rene, additional, Olin, Anna‐Carin, additional, Sergejeva, Svetlana, additional, Simpson, Angela, additional, Sterk, Peter J., additional, Tufvesson, Ellen, additional, Agache, Ioana, additional, and Seys, Sven F., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Severe asthma in children and adolescents
- Author
-
Hamelmann, Eckard, primary, Szefler, Stanley J., additional, and Lau, Susanne, additional
- Published
- 2019
- Full Text
- View/download PDF
14. EAACI Biologicals Guidelines—Recommendations for severe asthma.
- Author
-
Agache, Ioana, Akdis, Cezmi A., Akdis, Mubeccel, Canonica, Giorgio Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, Chu, Derek K., Del Giacco, Stefano, Eiwegger, Thomas, Flood, Breda, Firinu, Davide, Gern, James E., Hamelmann, Eckard, Hanania, Nicola, Hernández‐Martín, Irene, Knibb, Rebeca, Mäkelä, Mika, Nair, Parameswaran, and O'Mahony, Liam
- Subjects
BIOLOGICALS ,ASTHMA ,GUIDELINES ,TREATMENT duration - Abstract
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based) and its cost‐effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
- Author
-
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, Ballmer-Weber B, Bangert C, Ben-Shoshan M, Bernstein JA, Bindslev-Jensen C, Brockow K, Brzoza Z, Chong Neto HJ, Church MK, Criado PR, Danilycheva IV, Dressler C, Ensina LF, Fonacier L, Gaskins M, Gáspár K, Gelincik A, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Grosber M, Hamelmann E, Hébert J, Hide M, Kaplan A, Kapp A, Kessel A, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Lauerma A, Leslie TA, Magerl M, Makris M, Meshkova RY, Metz M, Micallef D, Mortz CG, Nast A, Oude-Elberink H, Pawankar R, Pigatto PD, Ratti Sisa H, Rojo Gutiérrez MI, Saini SS, Schmid-Grendelmeier P, Sekerel BE, Siebenhaar F, Siiskonen H, Soria A, Staubach-Renz P, Stingeni L, Sussman G, Szegedi A, Thomsen SF, Vadasz Z, Vestergaard C, Wedi B, Zhao Z, and Maurer M
- Subjects
- Chronic Disease, Humans, Prevalence, Quality of Life, Angioedema diagnosis, Angioedema etiology, Angioedema therapy, Asthma, Urticaria diagnosis, Urticaria epidemiology, Urticaria etiology
- Abstract
This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria., (© 2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
16. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA 2 LEN consensus.
- Author
-
Hagemann J, Onorato GL, Jutel M, Akdis CA, Agache I, Zuberbier T, Czarlewski W, Mullol J, Bedbrook A, Bachert C, Bennoor KS, Bergmann KC, Braido F, Camargos P, Caraballo L, Cardona V, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Correia-de-Sousa J, Del Giacco S, Dokic D, Dykewicz M, Ebisawa M, El-Gamal Y, Emuzyte R, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Gemicioglu B, Gomez RM, Gotua M, Haahtela T, Hamelmann E, Iinuma T, Ivancevich JC, Jassem E, Kalayci O, Kardas P, Khaitov M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Lipworth B, Makris M, Maspero JF, Miculinic N, Mihaltan F, Mohammad Y, Montefort S, Morais-Almeida M, Mösges R, Naclerio R, Neffen H, Niedoszytko M, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pereira A, Pfaar O, Plavec D, Popov TA, Prokopakis EP, Puggioni F, Raciborski F, Reijula J, Regateiro FS, Reitsma S, Romano A, Rosario N, Rottem M, Ryan D, Samolinski B, Sastre J, Solé D, Sova M, Stellato C, Suppli-Ulrik C, Tsiligianni I, Valero A, Valiulis A, Valovirta E, Vasankari T, Ventura MT, Wallace D, Wang Y, Williams S, Yorgancioglu A, Yusuf OM, Zernotti M, Bousquet J, and Klimek L
- Subjects
- Consensus, Humans, SARS-CoV-2, Asthma, COVID-19, Common Cold, Rhinitis, Allergic diagnosis
- Abstract
Background: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases., Methods: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis., Results: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001)., Conclusions: This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire., (© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
17. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).
- Author
-
Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bennoor KS, Berghea EC, Bergmann KC, Blain H, Bonini M, Bosnic-Anticevich S, Boulet LP, Brussino L, Buhl R, Camargos P, Canonica GW, Cardona V, Casale T, Chinthrajah S, Akdis M, Chivato T, Christoff G, Cruz AA, Czarlewski W, Del Giacco S, Du H, El-Gamal Y, Fokkens WJ, Fonseca JA, Gao Y, Gaga M, Gemicioglu B, Gotua M, Haahtela T, Halpin D, Hamelmann E, Hoffmann-Sommergruber K, Humbert M, Ilina N, Ivancevich JC, Joos G, Khaitov M, Kirenga B, Knol EF, Ko FW, Koskinen S, Kowalski ML, Kraxner H, Kudlay D, Kuna P, Kupczyk M, Kvedariene V, Abdul Latiff AH, Le LT, Levin M, Larenas-Linnemann D, Louis R, Masjedi MR, Melén E, Mihaltan F, Milenkovic B, Mohammad Y, Morais-Almeida M, Mullol J, Namazova L, Neffen H, Nunes E, O'Byrne P, O'Hehir R, O'Mahony L, Ohta K, Okamoto Y, Onorato GL, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pigearias B, Popov TA, Puggioni F, Regateiro FS, Rolla G, Rottem M, Samolinski B, Sastre J, Schwarze J, Sheikh A, Scichilone N, Soto-Quiros M, Soto-Martinez M, Sova M, Nicola S, Stelmach R, Suppli-Ulrik C, Taborda-Barata L, To T, Tomazic PV, Toppila-Salmi S, Tsiligianni I, Usmani O, Valiulis A, Ventura MT, Viegi G, Vontetsianos T, Wang Y, Williams S, Wong GWK, Yorgancioglu A, Zernotti M, Zidarn M, Zuberbier T, and Agache I
- Subjects
- Angiotensin-Converting Enzyme 2 physiology, Asthma drug therapy, Humans, Asthma complications, COVID-19 etiology, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.